KHB(SZ:002022) Zheng Quan Ri Bao Zhi Sheng·2026-01-16 10:04Group 1 - The core viewpoint of the article highlights that Kehua Bio is actively expanding its overseas market presence while leveraging its 40 years of experience in the in vitro diagnostic industry [1] - The company has established a sales network in Europe through its Italian subsidiary TGS, aiming to enhance its market reach in that region [1] - Kehua Bio has developed local service systems in several countries, including the Netherlands, South Korea, Kazakhstan, Thailand, Vietnam, Sri Lanka, Pakistan, Myanmar, and Peru, successfully registering and selling diagnostic instruments and reagents [1] Group 2 - According to the company's semi-annual report for 2025, the overseas operating revenue for the first half of 2025 reached 228,042,894.49 yuan, representing a year-on-year growth of 20.16% [1]